J Breast Cancer.  2006 Sep;9(3):230-234. 10.4048/jbc.2006.9.3.230.

Application Patterns of Sentinel Lymph Node Biopsy in Korean Breast Cancers

• Yang JH
• Kim DG
• Woo SW
• Kim JH
• Nam SJ

• KMID: 2286653
• DOI: http://doi.org/10.4048/jbc.2006.9.3.230

Abstract

PURPOSE
The sentinel lymph node biopsy (SLNB) has revolutionized the management of breast cancer. Since October 1995, when we first applied the SLNB for treatment of breast cancer, it has quickly become the standard of care for the management of breast cancer in Korea. Herein we provide preliminary nation-wide data on the use of SLNB.
METHODS
51 breast surgeons at 47 hospitals throughout Korea were surveyed and 33 breast surgeons answered. Questionnaires including 20 items were used to solicit information on the indications, methods, application patterns of SLNB, including the other surgical issues. The answers from 33 breast surgeons were used for the analysis.
RESULTS
Twenty-six of the 33 surgeons were applying SLNB for breast cancer. 11 surgeons have been applying SLNB more than 2 years. The most common indications for the SLNB were (1) no suggested axillary lymph node metastasis and (2) tumor size less than 3 cm. According to the detection methods, radioisotope tracer only was used in 38.5%, dye only in 26.9% and combination of radioisotope trace with dye in 34.6%. The most preferred dye was isosulfan blue followed by methylene blue. The most preferred radioisotope tracers were 99mTc-tin colloid and 99mTc-antimony. The most favorable injection site was subareolar area. Most surgeons performed frozen section biopsies after SLNB. Many surgeons agreed to accreditation after 20 learning cases.
CONCLUSION
SLNB becomes the standard of treatments for breast cancer in Korea. A systematic education program for SLNB is required.

Keyword

Sentinel lymph node biopsy; Breast cancer

MeSH Terms

Accreditation
Biopsy
Breast Neoplasms
Breast*
Colloids
Education
Frozen Sections
Korea
Learning
Lymph Nodes
Methylene Blue
Neoplasm Metastasis
Sentinel Lymph Node Biopsy*
Standard of Care
Surveys and Questionnaires
Colloids
Methylene Blue

Reference

1. Yang JH, Nam SK, Lee BB. Significance of sentinel node biopsy in operable breast cancer. J Korean Surg Soc. 1997. 52:940–948.

2. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994. 220:391–401.

3. Lyman GH, Giuliano AE, Somerfield MR, Benson AB, Borderka DC, Burstein HJ, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early stage breast cancer. J Clin Oncol. 2005. 23:7703–7713.

4. Lucci A, Kelemen PR, Miller C, Chardkoff L, Wilson L. National practice patterns of sentinel lymph node dissection for breast carcinoma. J Am Coll Surg. 2001. 192:453–458.

5. Giuliano AE. Sentinel node biopsy: Standard of care. Breast J. 2003. 9:53–56.

6. Tafra L, McMaster KM, Whitworth P, Edwards MJ. Credentialing issues with sentinel lymph node staging for breast cancer. Am J Surg. 2000. 180:268–273.

7. Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. A randomized comparision of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003. 349:546–553.